{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T05:42:11Z","timestamp":1774071731061,"version":"3.50.1"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010897","name":"Newton Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejphar.2022.175024","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T01:59:54Z","timestamp":1652493594000},"page":"175024","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions"],"prefix":"10.1016","volume":"926","author":[{"given":"You","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shams F.","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2556-1256","authenticated-orcid":false,"given":"Asma BM.","family":"Buanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175024_bib1","author":"Aadi"},{"key":"10.1016\/j.ejphar.2022.175024_bib2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1464-410X.2007.07120.x","article-title":"Influence of intravesical potassium on pelvic floor activity in women with recurrent urinary tract infections: comparative urodynamics might lead to enhanced detection of dysfunctional voiding","volume":"100","author":"Akkad","year":"2007","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2022.175024_bib3","article-title":"MP43-09 phase I trial of intravesical Bacillus Calmette-Gu\u00e9rin combined with intravenous pembrolizumab in high grade nonmuscle invasive bladder cancer","volume":"201","author":"Alanee","year":"2019","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib4","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.juro.2014.03.101","article-title":"Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer","volume":"192","author":"Arends","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib5","author":"AsierisPharma"},{"key":"10.1016\/j.ejphar.2022.175024_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update","author":"Babjuk","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib7","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.urolonc.2012.02.007","article-title":"Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL)","volume":"31","author":"Bader","year":"2013","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib8","first-page":"176","article-title":"VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer","volume":"10","author":"Biggers","year":"2008","journal-title":"Curr. Opin. Mol. Therapeut."},{"key":"10.1016\/j.ejphar.2022.175024_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.tps4590","article-title":"A randomized, prospective, phase II study to determine the efficacy of BCG given in combination with panvac versus BCG alone in adults with high grade non-muscle invasive bladder cancer who failed at least one induction course of BCG","volume":"32","author":"Brancato","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of bacillus calmette-gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose an","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib11","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.hoc.2021.02.003","article-title":"Current therapy and emerging intravesical agents to treat non-muscle invasive bladder cancer","volume":"35","author":"Bree","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ejphar.2022.175024_bib12","series-title":"TNM Classification of Malignant Tumours","year":"2017"},{"key":"10.1016\/j.ejphar.2022.175024_bib13","author":"Bristol-Myers Squibb"},{"key":"10.1016\/j.ejphar.2022.175024_bib14","series-title":"Non-Muscle Invasive Bladder Cancer","article-title":"Study of CG0070 given in combination with pembrolizumab","author":"CG Oncology","year":"2022"},{"key":"10.1016\/j.ejphar.2022.175024_bib15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/JCO.2021.39.6_suppl.510","article-title":"Phase II\/III clinical results of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients","volume":"39","author":"Chamie","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175024_bib17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5489\/cuaj.6101","article-title":"Emerging intravesical therapies for the management of bacillus calmette-gu\u00e9rin (bcg)-unresponsive non-muscle-invasive bladder cancer: charting a path forward","volume":"14","author":"Chehroudi","year":"2020","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.ejphar.2022.175024_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/bju.13088","article-title":"Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer","volume":"117","author":"Cockerill","year":"2016","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2022.175024_bib19","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3233\/BLC-170095","article-title":"Single arm phase I\/II study of everolimus and intravesical gemcitabine in patients with primary or secondary carcinoma in situ of the bladder who failed bacillus calmette guerin (NCT01259063)","volume":"3","author":"Dalbagni","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ejphar.2022.175024_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2019.07.022","article-title":"An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine\/docetaxel for nonmuscle-invasive bladder cancer","volume":"38","author":"Daniels","year":"2020","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3233\/BLC-180191","article-title":"Hyperthermic intravesical chemotherapy for BCG unresponsive non-muscle invasive bladder cancer patients","volume":"4","author":"De Jong","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ejphar.2022.175024_bib22","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus Calmette\u2013Gu\u00e9rin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res. Rep. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1200\/JCO.2017.35.6_suppl.313","article-title":"A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder","volume":"35","author":"DeCastro","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus calmette-gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"Decastro","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib25","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/j.urolonc.2012.04.010","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin","volume":"31","author":"Dinney","year":"2013","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib26","series-title":"Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs: World Health Organization Classification of Tumours","author":"Eble","year":"2004"},{"key":"10.1016\/j.ejphar.2022.175024_bib27","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1097\/01.ju.0000092238.15685.10","article-title":"Androgen dependent regulation of bacillus calmette-guerin induced interleukin-6 expression in human transitional carcinoma cell lines","volume":"170","author":"Fanghong","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib28","series-title":"BCG-unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry","author":"Food and Drug administration","year":"2018"},{"key":"10.1016\/j.ejphar.2022.175024_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0022-5347(17)40882-2","article-title":"Intravesical combination chemotherapy with mitomycin C and doxorubicin for carcinoma in situ of the bladder","volume":"141","author":"Fukui","year":"1989","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12967-019-1778-6","article-title":"Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model","volume":"17","author":"Furuya","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejphar.2022.175024_bib31","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S0022-5347(17)39547-2","article-title":"A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder","volume":"144","author":"Glashan","year":"1990","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib32","doi-asserted-by":"crossref","first-page":"54367","DOI":"10.1021\/acsami.0c15176","article-title":"Intravesical in situ immunostimulatory gel for triple therapy of bladder cancer","volume":"12","author":"Guo","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejphar.2022.175024_bib33","author":"Hoffmann-La Roche"},{"key":"10.1016\/j.ejphar.2022.175024_bib34","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1021\/bm300739w","article-title":"Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder cancer therapy","volume":"13","author":"Huang","year":"2012","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejphar.2022.175024_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/1078-1439(95)00039-K","article-title":"Failure of lntravesical interferon-alfa-2b for the treatment of patients with superficial bladder cancer previously failing intravesical BCG therapy","volume":"3","author":"Hudson","year":"1995","journal-title":"Urol. Oncol. 1."},{"key":"10.1016\/j.ejphar.2022.175024_bib36","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/cells10051169","article-title":"Sex hormone receptor signaling in bladder cancer: a potential target for enhancing the efficacy of conventional non-surgical therapy","volume":"10","author":"Ide","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2022.175024_bib37","author":"ImmunityBio"},{"key":"10.1016\/j.ejphar.2022.175024_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/02656736.2014.882021","article-title":"A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer","volume":"30","author":"Inman","year":"2014","journal-title":"Int. J. Hyperther."},{"key":"10.1016\/j.ejphar.2022.175024_bib40","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41585-019-0220-4","article-title":"Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer","volume":"16","author":"Joice","year":"2019","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2B for reducing recurrence of superficial bladder cancer{star, open","author":"Joudi","year":"2006","journal-title":"Urol. Oncol."},{"issue":"10061","key":"10.1016\/j.ejphar.2022.175024_bib42","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ejphar.2022.175024_bib43","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat. Rev. Urol."},{"issue":"10","key":"10.1016\/j.ejphar.2022.175024_bib45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib46","doi-asserted-by":"crossref","first-page":"E690","DOI":"10.5489\/cuaj.3320","article-title":"Cua guidelines on the management of non-muscle invasive bladder cancer","volume":"9","author":"Kassouf","year":"2015","journal-title":"J. Can. Urol. Assoc."},{"issue":"1","key":"10.1016\/j.ejphar.2022.175024_bib47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ucl.2019.09.014","article-title":"Salvage therapy for non\u2013muscle-invasive bladder cancer: novel intravesical agents","volume":"47","author":"Khaled","year":"2020","journal-title":"Urol. Clin."},{"key":"10.1016\/j.ejphar.2022.175024_bib48","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/iju.14153","article-title":"Bacillus Calmette\u2013Gu\u00e9rin-unresponsive non-muscle-invasive bladder cancer: its definition and future therapeutic strategies","volume":"27","author":"Kikuchi","year":"2020","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib49","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/iju.12639","article-title":"Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?","volume":"22","author":"Kiss","year":"2015","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib51","series-title":"Side Effects of Intravesical BCG and Chemotherapy for Bladder Cancer: what They Are and How to Manage Them","author":"Koch","year":"2021"},{"issue":"10","key":"10.1016\/j.ejphar.2022.175024_bib52","article-title":"BCG immunotherapy for transitional-cell carcinoma in situ of the bladder","volume":"9","author":"Lamm","year":"1995","journal-title":"Oncology"},{"key":"10.1016\/j.ejphar.2022.175024_bib53","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.ejphar.2022.175024_bib54","doi-asserted-by":"crossref","first-page":"101","DOI":"10.5213\/inj.1632664.332","article-title":"Implantable devices for sustained, intravesical drug delivery","volume":"20","author":"Lee","year":"2016","journal-title":"Int. Neurourol. J."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175024_bib55","doi-asserted-by":"crossref","first-page":"F867","DOI":"10.1152\/ajprenal.2000.278.6.F867","article-title":"Everything you wanted to know about the bladder epithelium but were afraid to ask","volume":"278","author":"Lewis","year":"2000","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"4","key":"10.1016\/j.ejphar.2022.175024_bib56","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3109\/02656736.2016.1155760","article-title":"Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations","volume":"32","author":"Liem","year":"2016","journal-title":"Int. J. Hyperther."},{"key":"10.1016\/j.ejphar.2022.175024_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1043-4666(02)00490-8","article-title":"Role of Th1 and Th2 cytokines in BCG-induced IFN-\u03b3 production: cytokine promotion and simulation of BCG effect","volume":"21","author":"Luo","year":"2003","journal-title":"Cytokine"},{"key":"10.1016\/j.ejphar.2022.175024_bib59","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/j.ejca.2015.07.028","article-title":"Urinary tract cancer survival in Europe 1999-2007: results of the population-based study EUROCARE-5","volume":"51","author":"Marcos-Gragera","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2022.175024_bib60","first-page":"43","article-title":"Non-muscle-invasive bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies","author":"Matulewicz","year":"2020","journal-title":"Rev. Urol. 2292)"},{"key":"10.1016\/j.ejphar.2022.175024_bib61","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-5347(18)33076-3","article-title":"840: intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer","volume":"175","author":"Maymi","year":"2006","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib62","author":"McKiernan"},{"key":"10.1016\/j.ejphar.2022.175024_bib63","author":"Meeks"},{"key":"10.1016\/j.ejphar.2022.175024_bib66","author":"Merck Sharp & Dohme Corp"},{"issue":"3","key":"10.1016\/j.ejphar.2022.175024_bib67","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3233\/BLC-179018","article-title":"The BCG shortage","volume":"3","author":"Messing","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ejphar.2022.175024_bib68","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1001\/jama.2018.4657","article-title":"Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence SWOG S0337 randomized clinical trial","volume":"319","author":"Messing","year":"2018","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.ejphar.2022.175024_bib69","doi-asserted-by":"crossref","first-page":"6601","DOI":"10.1002\/adfm.201401076","article-title":"Nanoparticles with precise ratiometric Co-loading and Co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer","volume":"24","author":"Miao","year":"2014","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.ejphar.2022.175024_bib70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ejphar.2022.175024_bib71","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1158\/1535-7163.MCT-20-0050","article-title":"Androgen receptor signaling reduces the efficacy of Bacillus calmette-gu\u00e9rin therapy for bladder cancer via modulating rab27b-induced exocytosis","volume":"19","author":"Mizushima","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2022.175024_bib72","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijpharm.2014.01.021","article-title":"Bladder tissue permeability and transport modelling of intravesical alum, lidocaine hydrochloride, methylprednisolone hemisuccinate and mitomycin C","volume":"464","author":"Moch","year":"2014","journal-title":"Int. J. Pharm."},{"issue":"5","key":"10.1016\/j.ejphar.2022.175024_bib73","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/MOU.0000000000000078","article-title":"The burden of bladder cancer care: direct and indirect costs","volume":"24","author":"Mossanen","year":"2014","journal-title":"Curr. Opin. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib74","series-title":"Histological Typing of Urinary Bladder Tumours","author":"Mostofi","year":"2012"},{"issue":"1","key":"10.1016\/j.ejphar.2022.175024_bib75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ucl.2019.09.011","article-title":"Intravesical gene therapy","volume":"47","author":"Narayan","year":"2020","journal-title":"Urol. Clin."},{"key":"10.1016\/j.ejphar.2022.175024_bib77","series-title":"Durvalumab and Vicineum in Subjects with High-Grade Non-muscle-invasive Bladder Cancer Previously Treated with Bacillus Calmette-Guerin","year":"2022"},{"key":"10.1016\/j.ejphar.2022.175024_bib78","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.juro.2009.06.017","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after Bacillus calmette-guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bju.12566","article-title":"Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base","volume":"114","author":"Nielsen","year":"2014","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2022.175024_bib80","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11934-019-0952-y","article-title":"Current clinical trials in non-muscle-invasive bladder cancer: heightened need in an era of chronic BCG shortage","volume":"20","author":"Packiam","year":"2019","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.ejphar.2022.175024_bib81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/MOU.0000000000000863","article-title":"The current landscape of salvage therapies for patients with bacillus Calmette-Gu\u00e9rin unresponsive nonmuscle invasive bladder cancer","volume":"31","author":"Packiam","year":"2021","journal-title":"Curr. Opin. Urol."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175024_bib82","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00211413","article-title":"Mechanisms of action of bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder cancer","volume":"11","author":"Patard","year":"1993","journal-title":"World J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.539527","article-title":"Novel combination therapies for the treatment of bladder cancer","volume":"10","author":"Peng","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.ejphar.2022.175024_bib84","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.tibtech.2019.12.012","article-title":"Intravesical hydrogels as drug reservoirs","volume":"38","author":"Qiu","year":"2020","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.ejphar.2022.175024_bib85","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cbCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2022.175024_bib86","first-page":"9231","article-title":"Bacillus Calmette-Gu\u00e9rin induces rapid gene expression changes in human bladder cancer cell lines that may modulate its survival","volume":"15","author":"Rahmat","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejphar.2022.175024_bib87","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib88","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bju.12261","article-title":"Modulating the immune response to Bacillus Calmette-Gu\u00e9rin (BCG): a novel way to increase the immunotherapeutic effect of BCG for treatment of bladder cancer?","volume":"112","author":"Sapre","year":"2013","journal-title":"BJU Int."},{"key":"10.1016\/j.ejphar.2022.175024_bib89","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1158\/1535-7163.MCT-14-1055-T","article-title":"Antiandrogen therapy with hydroxyflutamide or androgen receptor degradation enhancer ASC-J9 enhances BCG efficacy to better suppress bladder cancer progression","volume":"14","author":"Shang","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejphar.2022.175024_bib90","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2014.09.026","article-title":"Sequential combination of mitomycin C plus bacillus calmette-gu\u00e9rin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomiz","volume":"67","author":"Solsona","year":"2015","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib91","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00345-015-1595-3","article-title":"Efficacy and safety of a new device for intravesical thermochemotherapy in non-grade 3 BCG recurrent NMIBC: a phase I\u2013II study","volume":"34","author":"Soria","year":"2016","journal-title":"World J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib92","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","article-title":"Prognostic performance and reproducibility of the 1973 and 2004\/2016 world Health organization grading classification systems in non\u2013muscle-invasive bladder cancer: a European association of Urology non-muscle invasive bladder cancer guidelines panel syst","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib93","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1158\/1078-0432.CCR-04-2291","article-title":"Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (taxol)","volume":"11","author":"Sparreboom","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2022.175024_bib94","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ejphar.2022.175024_bib95","first-page":"761","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"63","author":"Steinberg","year":"2000","journal-title":"The Valrubicin Study Group [published correction appears in J Urol"},{"key":"10.1016\/j.ejphar.2022.175024_bib96","first-page":"65","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bl. cancer"},{"key":"10.1016\/j.ejphar.2022.175024_bib97","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.urolonc.2017.07.024","article-title":"Quadruple immunotherapy of Bacillus Calmette-Gu\u00e9rin, interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor as salvage therapy for non\u2013muscle-invasive bladder cancer","volume":"35","author":"Steinberg","year":"2017","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.ejphar.2022.175024_bib98","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2022.175024_bib99","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","article-title":"Radiofrequency-induced thermo-chemotherapy effect versus a second course of Bacillus calmette-gu\u00e9rin or institutional standard in patients with recurrence of non\u2013muscle-invasive bladder cancer following induction or maintenance Bacillus calmette-gu\u00e9rin Th","volume":"75","author":"Tan","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib101","author":"Theralase"},{"key":"10.1016\/j.ejphar.2022.175024_bib102","first-page":"492","article-title":"Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder","volume":"37","author":"Tyagi","year":"2019","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.ejphar.2022.175024_bib103","author":"Valera Romero"},{"issue":"3","key":"10.1016\/j.ejphar.2022.175024_bib104","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"van Rhijn","year":"2009","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib105","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3233\/BLC-180187","article-title":"Intravesical radiofrequency-induced chemohyperthermia for carcinoma in situ of the urinary bladder: a retrospective multicentre study","volume":"4","author":"Van Valenberg","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.ejphar.2022.175024_bib106","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11934-016-0594-2","article-title":"Experience with sequential intravesical gemcitabine and docetaxel as salvage therapy for non-muscle invasive bladder cancer","volume":"17","author":"Velaer","year":"2016","journal-title":"Curr. Urol. Rep."},{"key":"10.1016\/j.ejphar.2022.175024_bib107","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000341912","article-title":"Thermochemotherapy for non-muscle-invasive bladder cancer: is there a chance to avoid early cystectomy?","volume":"89","author":"Volpe","year":"2012","journal-title":"Urol. Int."},{"key":"10.1016\/j.ejphar.2022.175024_bib108","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/S0022-5347(05)66239-8","article-title":"Clinical experience with 5-aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer","volume":"165","author":"Waidelich","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.ejphar.2022.175024_bib109","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13287-018-1035-6","article-title":"Urothelium with barrier function differentiated from human urine-derived stem cells for potential use in urinary tract reconstruction","volume":"9","author":"Wan","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ejphar.2022.175024_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-9056(19)31328-4","article-title":"PT124 - a phase 2, randomized study of nivolumab or nivolumab plus BMS-986205 with or without intravesical bacillus Calmette-Guerin in patients with bacillus Calmette-Guerin\u2013unresponsive, high-risk, non-muscle invasive bladder cancer: CheckMate 9UT","volume":"18","author":"Witjes","year":"2019","journal-title":"Eur. Urol. Suppl."},{"key":"10.1016\/j.ejphar.2022.175024_bib111","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41598-018-19199-z","article-title":"The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection","volume":"8","author":"Wong","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2022.175024_bib112","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1039\/c3tb21625j","article-title":"Bifunctional pH-sensitive Zn(ii)-curcumin nanoparticles\/siRNA effectively inhibit growth of human bladder cancer cells in vitro and in vivo","volume":"2","author":"Xing","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ejphar.2022.175024_bib113","doi-asserted-by":"crossref","first-page":"111773","DOI":"10.1016\/j.msec.2020.111773","article-title":"Stereolithography (SLA) 3D printing of a bladder device for intravesical drug delivery","volume":"120","author":"Xu","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"issue":"11","key":"10.1016\/j.ejphar.2022.175024_bib114","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1080\/17425247.2020.1810016","article-title":"Current status of the development of intravesical drug delivery systems for the treatment of bladder cancer","volume":"17","author":"Yoon","year":"2020","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.ejphar.2022.175024_bib115","first-page":"169","article-title":"Novel targeted bladder drug-delivery systems: a review","volume":"7","author":"Zacch\u00e8","year":"2015","journal-title":"Res. Rep. Urol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922002850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922002850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:17:37Z","timestamp":1762143457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922002850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":111,"alternative-id":["S0014299922002850"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175024","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175024"}}